26 results about "Hepatovirus" patented technology

The invention discloses a method for predicting the survival state of duck against hepatitis A virus infection. The method comprises the following steps: (1) constructing a PCA (Principal Component Analysis) prediction model by taking the contents of IFN-alpha and IFN-beta of duck blood as variables; (2) measuring the contents of IFN-alpha and IFN-beta in the duck blood to be measured; and (3) substituting the measured contents of IFN-alpha and IFN-beta in the duck blood into the prediction model, and predicting the anti-hepatitis A virus infection survival state of the duck to be detected according to the family background of the individual in combination with the output result of the prediction model. According to the method, ROC curves and corresponding AUC values of different prediction models in the aspect of predicting the survival state are compared, and the result shows that the AUC value of the PCA prediction model is the highest, and the sensitivity and the specificity are most prominent. Based on the prediction model provided by the invention, the Beijing duck individuals or strains with strong disease resistance can be rapidly screened, and the prediction model has an application prospect in duck disease resistance breeding or duck virus hepatitis prevention.

The present disclosure relates to a ribavirin derivative-embedded double-stranded siRNA analogue, a conjugate comprising the same, and salts and uses thereof. The double-stranded siRNA analogue, the conjugate comprising the same, and the salts thereof of the present disclosure can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

The invention discloses a traditional Chinese medicine composition for treating fatty liver and reducing hepatitis B virus load. The traditional Chinese medicine composition is prepared from the following raw material medicines: prepared rehmannia root, rhizoma polygonati (processed), radix asparagi, schisandra chinensis, hawthorn leaf, glossy privet fruit, oriental wormwood, radix curcumae, illicium verum and salvia miltiorrhiza. According to the technology of the invention, liver treatment is a preparation based on compatibility of traditional Chinese medicine syndrome differentiation in which liver, spleen and kidney are treated at the same time, fat in the liver can be effectively removed, damage of hepatitis B virus to the liver can be reduced, hepatitis B virus reproduction can be effectively inhibited, the load of hepatitis B virus can be reduced, and multiple curative effects of liver treatment, liver nourishing and liver protection can be realized; the traditional Chinese medicine composition is superior to other treatment medicines and treatment technologies for fatty liver in modern medicine. The method can be widely applied to the fields of medicines, functional foods, health-preserving and health-care products, common foods and beverages and the like.

The invention discloses a screening method of hepatitis B virus antigen epitope peptides, computer equipment and a storage medium, and the method comprises the following steps: generating an initial screening library based on all proteome sequences of hepatitis B viruses, the initial screening library comprising a plurality of antigen epitope peptides to be screened; an antigen epitope peptide-MHC compound corresponding to each antigen epitope peptide is constructed; based on the antigen epitope peptide-MHC compound, a conformational trajectory of the antigen epitope peptide-MHC compound is obtained through molecular dynamics simulation; calculating the binding free energy of each antigen epitope peptide and the MHC based on the conformation trajectory, and sorting the plurality of antigen epitope peptides based on the binding free energy to obtain a first sorting set; based on the antigen epitope peptide-MHC compound, sorting the plurality of antigen epitope peptides by using a machine learning model to obtain a second sorting set; and screening the plurality of to-be-screened antigen epitope peptides based on the first sorting set and the second sorting set to obtain the screened antigen epitope peptides.

Provided are a pharmaceutically acceptable salt, a crystal form and a preparation method of a TLR7 / 8 agonist compound of formula I, a pharmaceutical composition containing the pharmaceutically acceptable salt, and a medical use of the pharmaceutically acceptable salt, which can be used for preparing drugs for preventing or treating Toll-like receptor 7 / 8 (TLR7 / 8) related diseases, such as a new therapeutic agent for human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and cancer.

The application provides a hepatitis E virus nucleic acid detection primer, probe and kit, wherein according to a target sequence of a hepatitis E virus gene, a primer and a probe sequence in an asymmetric primer ERA detection system are designed, screened, and optimized in terms of an upstream primer ratio, a downstream primer ratio and an amplification reaction system, so that the primer and the probe can specifically recognize a nucleic acid sequence of the hepatitis E virus, non-specific binding with other irrelevant nucleic acids is reduced, and thus the specificity of detection is improved; meanwhile, efficient amplification of the hepatitis E virus nucleic acid is realized, and even in the case of extremely low content of the virus nucleic acid, the hepatitis E virus nucleic acid can be accurately detected, and thus the sensitivity and the amplification efficiency of detection are improved.

The application discloses application of coenzyme Q10 and a composition containing coenzyme Q10 in preparation of a medicine for preventing and treating duck hepatitis A virus type 1, and relates to the technical field of veterinary antiviral medicines. The application finds through experiments that coenzyme Q10 and the composition containing coenzyme Q10 have a protective effect on duck hepatitis A virus type 1 infection. The composition contains coenzyme Q10 and egg yolk antibodies. The combination of coenzyme Q10 and egg yolk antibodies can relieve inflammatory reactions caused by duck hepatitis A virus type 1, reduce liver oxidative application, alleviate liver function damage caused by duck hepatitis A virus type 1, and reduce the viral load of duck hepatitis A virus type 1, so that the dual synergy of 'antiviral' and 'anti-inflammatory liver protection' is realized. The application first finds the application value of the combination of coenzyme Q10 and egg yolk antibodies in the prevention and treatment of DHAV-1 infection, and provides a new technical strategy for the prevention and treatment of duck viral hepatitis.

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

The invention provides an integrated DNA interference excluding in-situ hybridization probe and an in-situ hybridization method for detecting hepatitis B virus cccDNA, the in-situ hybridization probe is designed based on a Basescope detection method, and comprises an HBV cccDNA probe specifically targeting an integrated breakpoint of HBV negative chain DNA, an HBV DNA probe targeting an HBV negative chain, an HBV cccDNA probe targeting an HBV negative chain, an HBV cccDNA probe targeting an HBV negative chain, an HBV cccDNA probe targeting an HBV negative chain, and an HBV cccDNA probe targeting an HBV negative chain. The HBV RNA probe with the targeted HBV positive strand gap structure and the matched ribonuclease of the HBV RNA probe can be used for detecting cccDNA and integrating HBV DNA after being treated, and the targeting sequences of the HBV cccDNA, the HBV DNA and the HBV RNA probe are respectively shown as SEQ ID No.1 to SEQ ID No.3. The in-situ hybridization probe and the in-situ hybridization method can be applied to screening medicines for preventing or treating hepatitis B virus infection and researching the life cycle of the hepatitis B virus, so that the understanding on the characteristics of the hepatitis B virus is promoted, and the evaluation on a treatment strategy is optimized.

The application discloses a postpartum hepatitis C referral management system based on a mobile terminal and relates to the medical management field.The system comprises a medical communication module, a data entry module and an index preset module.The medical communication module is used for integrating the communication permission of the mobile terminal and providing a plurality of communication channels.The data entry module is used for periodically collecting and entering the liver function indexes, the hepatitis C virus load data and the emotional evaluation scores of puerpera through the medical communication module.The index preset module is used for presetting the benchmark feeding indexes of future periods according to a newborn growth model.The risk prediction module is used for collecting the data of the current period data entry module and the preset feeding indexes of the next period based on the risk prediction model.The risk coefficient of breastfeeding behavior is dynamically predicted by using the risk prediction model, the potential risks under different feeding schemes are quantitatively evaluated, the high-risk puerpera are early identified, the disease deterioration or the risk of mother-to-child transmission caused by delayed intervention is reduced, the human error is reduced, and the accuracy and response speed of postpartum hepatitis C management are improved.

Provided are a ribavirin derivative-embedded double-stranded siRNA analog, a conjugate comprising the same, and a salt and use thereof. The provided double-stranded siRNA analog, the conjugate comprising the same, and the salt thereof can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

The invention discloses a nano antibody targeting a hepatitis B surface antigen and application of the nano antibody. The nano antibody has an amino acid sequence as shown in SEQ ID NO: 1-5, and has high affinity to HBsAg. The nano antibody not only can effectively neutralize hepatitis B virus, but also can enter cells to realize'multi-link and all-directional 'inhibition of virus life cycle, including inhibition of virus RNA transcription, protein expression, nucleocapsid assembly, DNA replication and particle secretion, and can significantly down-regulate HNF4alpha, Sp1 and other key transcription factors in host hepatocytes. The antibody can be efficiently expressed in a prokaryotic or eukaryotic system. The PEGylated derivative (such as Nb1-PEG40) can prolong the half-life period, and shows stronger effects of clearing serum HBsAg and inhibiting liver virus replication in an HBV infected mouse model. The invention provides a new strategy and drug candidate for hepatitis B treatment.

Embodiments described herein provide orthohepadnavirus capsid protein (Cp) heterodimers, bicistronic vectors encoding the heterodimers, and methods for producing the heterodimers. The heterodimers can be used to form mosaic virus-like particles. In certain embodiments, the heterodimers can form a hexamer, which in turn can be used to nucleate capsid formation, resulting in a Janus particle-like virus-like particle. The hexamer's can then be removed, leaving holey capsids. The capsids can be loaded with, for example, one or more polypeptides, small molecules, or a combination of polypeptides and small molecules. The holes of the holey capsids can be filled with another orthohepadnavirus heterodimer or a homodimer.

The invention discloses a nano antibody targeting a hepatitis B core antigen as well as a coding gene and application thereof, and relates to the technical field of biological medicines. The nano antibody comprises an amino acid sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 5, and can be specifically combined with HBcAg. The invention also relates to a coding nucleic acid, an expression vector, a host cell and a preparation method of the nano antibody, and application of the nano antibody in preparation of anti-hepatitis B virus drugs and diagnostic reagents. Experiments show that the nano antibody has high affinity of targeting HBcAg, can combine and destroy hepatitis B virus nucleocapsid assembly and inhibit secretion of virus proteins such as HBsAg, HBeAg and the like, and thus has good anti-hepatitis B virus activity.

Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and / or treating hepatitis B virus (HBV) and / or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and / or HDV and an organic anion transporting polypeptide (OATP) in the animal, and / or prevents or reduces the expression and / or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and / or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.

The utility model relates to the technical field of medical instruments, in particular to a hepatitis B virus adsorption device. The device comprises an adsorption assembly and a mounting assembly, the adsorption assembly comprises a circulation pipe body, a filtering sub-assembly detachably arranged in the circulation pipe body and a pair of installation connectors symmetrically arranged at the upper end and the lower end of the circulation pipe body and used for being communicated with the two hemodialysis pipes respectively. The mounting assembly comprises a pair of mounting shells which are symmetrically buckled on the left side and the right side of the circulating pipe body, a pair of clamping sub-assemblies which are symmetrically arranged on the opposite side faces of the two mounting shells left and right, and a fixing sub-assembly which is arranged between the mounting shells and the circulating pipe body and is used for fixing the mounting pipe body; each clamping sub-assembly comprises a pair of clamping plates which are symmetrically and rotationally arranged at the upper end and the lower end of the mounting shell; arc-shaped parts are arranged at the ends, away from each other, of the two clamping plates in each clamping sub-assembly. According to the device, the situation that the communicating position of the hemodialysis tube and the mounting connector is bent in the adsorption process, and blood passing is affected is avoided as much as possible.

The invention relates to the technical field of biological detection, and discloses an oligonucleotide composition, a kit and application. The composition disclosed by the invention can be used for rapidly and simultaneously detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus in a sample with high specificity, and has relatively high sensitivity and stability. Compared with the traditional detection methods such as pathogen separation, genome sequencing and the like, the efficiency of identifying and detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus by adopting the composition disclosed by the invention is effectively improved, the detection process is simple and convenient to operate, and the composition is suitable for large-scale popularization and application.

The application discloses a T cell receptor and application thereof, and relates to the technical field of biological medicine, wherein the T cell receptor can specifically combine with an epitope peptide of a hepatitis B virus surface antigen presented by an HLA-A*24:02 molecule, and the amino acid sequence of the epitope peptide is shown as SEQ ID NO:1. The T cell receptor comprises an alpha chain variable region and a beta chain variable region, the alpha chain variable region comprises a first CDR1, a first CDR2 and a first CDR3, and the beta chain variable region comprises a second CDR1, a second CDR2 and a second CDR3; the first CDR3 sequence of the alpha chain variable region comprises an amino acid sequence shown as SEQ ID NO:2, and the second CDR3 sequence of the beta chain variable region comprises an amino acid sequence shown as SEQ ID NO:3. The T cell receptor provided in the application can specifically combine with the epitope peptide of the hepatitis B virus surface antigen presented by the HLA-A*24:02 molecule, based on the T cell receptor, corresponding isolated polynucleotides, vectors and host cells can be constructed, thereby providing key core elements for preparing a pharmaceutical composition for preventing and / or treating hepatitis B virus related diseases.

The invention is applicable to the technical field of biological medicines, and provides a single-antigen or multi-antigen mRNA vaccine for preventing or treating hepatitis B virus infection and application thereof. The protein coded by mRNA comprises a fusion protein (Pan-HLA-DR-epitope-preS1-Fc) formed by fusing a hepatitis B virus surface antigen and / or a hepatitis B virus front surface antigen 1 with a pan-HLA-DR binding epitope and a human IgG1 Fc segment. After mRNA is wrapped into a delivery system through lipid nanoparticles, a single-antigen or multi-antigen mRNA vaccine is prepared. The mRNA vaccine preparation can specifically enhance humoral immune response and cellular immune response aiming at hepatitis B virus surface antigen and / or hepatitis B virus front surface antigen 1, and can be used for preventing and treating hepatitis B; all the components in the mRNA vaccine preparation can be widely obtained, the vaccine cost is effectively reduced, the vaccine yield is increased, and good practical application value is achieved.

This invention relates to the field of gene detection technology, and more particularly to a capture probe combination, a kit, and its application in hepatitis E virus whole-genome sequencing. The probe combination comprises probes with nucleotide sequences as shown in SEQ ID NO.1-SEQ ID NO.951. The applications include: (1) detecting hepatitis E virus, or preparing products for detecting hepatitis E virus; (2) whole-genome sequencing of hepatitis E virus, or preparing products for whole-genome sequencing of hepatitis E virus. This invention provides a set of probes for whole-genome sequencing of hepatitis E virus, which can specifically enrich ultra-low copy number hepatitis E virus genomes from high background host nucleic acids, and thus has significant application value in hepatitis E virus detection in various scenarios such as clinical diagnosis, epidemic tracing, virus mutation monitoring, food safety testing, and basic research.

This invention proposes a microfluidic chip for the combined detection of hepatitis A / hepatitis E virus IgM antibodies and its application. The chip includes a substrate and a cover plate pressed onto the substrate. The substrate and cover plate enclose a microchannel, which is provided with a labeling area and a detection area. The labeling area includes a first labeling area on the lower surface of the cover plate and a second labeling area on the upper surface of the substrate. The detection area includes an HEV-IgM antibody detection area on the lower surface of the cover plate and a HAV-IgM antibody detection area on the upper surface of the substrate. An IgG antibody capture area is provided on the upper surface of the substrate directly below the sample injection well. The IgG antibody capture area contains magnetic microspheres containing anti-human IgG antibodies. The first labeling area contains labeled HEV antigen, the second labeling area contains labeled anti-human IgM antibody, the HEV-IgM antibody detection area contains anti-human IgM antibody, and the HAV-IgM antibody detection area contains HAV antigen. The capture method and the indirect method are used in parallel to achieve the combined detection of IgM antibodies related to the two viruses.

This invention relates to pharmaceuticals and methods for clearing hepatitis B virus (HBV) cccDNA from the livers of hepatitis B virus-infected individuals. Specifically, this invention provides the use of HBV entry inhibitors that inhibit HBV entry into hepatocytes and, optionally, immunomodulatory agents that regulate anti-HBV immunity in the preparation of pharmaceutical combinations or kits used in methods for clearing HBV cccDNA from hepatitis B patients. This invention also provides corresponding pharmaceutical combinations and kits for the above-mentioned uses.

The invention relates to a new application of a homologous box gene, in particular to an application of a BARX homologous frame 1 (BARX1) and an NK1 homologous frame 1 (NKX1-1) in resisting hepatitis B virus (HBV). The invention discovers that BARX1 and NKX1-1 are novel host limiting factors of HBV for the first time. BARX1 and NKX1-1 synergistically inhibit HBV through dual mechanisms: on one hand, the degradation of HBx protein is horizontally promoted after transcription; on the other hand, the activity of an HBV enhancer II / core promoter is inhibited, so that the hepatitis B virus is inhibited. In-vivo and in-vitro experiments prove that HBV gene expression and genome replication can be remarkably reduced by overexpressing BARX1 or NKX1-1. The invention provides an effective molecular target for developing a novel anti-HBV drug and a gene therapy strategy.

This invention provides a capture probe set for whole-genome sequencing of hepatitis A virus (HAV). The nucleotide sequences of the capture probe set are shown in SEQ ID No:1 to SEQ ID No:880. This capture probe set can be used to prepare kits for whole-genome sequencing of HAV. This invention also provides a method for whole-genome sequencing of HAV using the capture probe set. The method involves liquid-phase hybridization of a total RNA library from a sample to be tested with the capture probe set. DNA fragments hybridized with the capture probe set are isolated from the hybridization reaction solution. These DNA fragments are then used as templates for capture-and-PCR amplification. The PCR products are sequenced, and after data analysis, the full-length HAV genome sequence is obtained. The capture probe set designed in this invention can capture the HAV genome. By optimizing the probe length, it can specifically enrich ultra-low copy numbers of the viral genome from high-background host nucleic acids, showing broad application prospects.

This invention discloses a Cherry Valley duck hepatoma cell line (DMH) and its applications. It relates to the field of biotechnology. It provides a method for establishing immortalized duck hepatoma cells and related applications. This invention has good market demand and application value. It provides stable cell material for scientific research on duck viral hepatitis virus and the development and production of vaccines. Based on a duck hepatoma model induced by diethylnitrosamine (DEN), this invention obtains a highly active and pure duck hepatoma cell line through standardized primary tumor cell isolation, culture, and identification procedures. This cell line can efficiently support the proliferation of waterfowl hepatotropic viruses, and is particularly suitable for the culture of duck viral hepatitis virus, providing an ideal cell carrier for waterfowl viral pathogen research and vaccine development.

A viral gene therapy vector for removing hepatitis B virus and application, relates to the field of biological medicine, especially to a gene therapy vector and its preparation method and application. To solve the problem that the existing viral gene therapy vector can only inhibit hepatitis B virus replication and cannot remove viral cccDNA. The vector comprises a promoter, an intron, an enhancer, a PGLYRP2 protein nuclear localization signal NLS functional domain coding gene, a PGLYRP2 protein HBV DNA binding domain coding gene, a PGLYRP2 protein secretion signal peptide functional domain coding gene, a PGLYRP2 protein HBV nuclear envelope binding functional domain coding gene and an IRES fragment. The viral gene therapy vector of the application can significantly promote the removal of HBV in the liver of mice. The viral gene therapy vector of the application is used for treating hepatitis B virus infection.